The multiple actions of corticotropin-releasing factor (CRF) on neuroendocrine and behavioural functions can now be examined using new, high affinity, non peptidic antagonists which exhibit central activity upon systemic application. We have shown that compound CP 154,526 (butyl-ethyl-[2.5-dimethyl-7-(2、4、6-trimethyphenyl)-7H-pyrrtly [2.3d]pyrimidin-4-yl]amine) displaces [125][Tyo]CRF from rat hippocampal CRF receptors (ICso= 0.5 nM) and from pituitary CRF receptors (ICso=0.04 nM). The same compound inhibits in a concentration-dependent manner the ovine CRF (0.1 ixM)-stimulated adenylate cyclase activity in membranes of a mouse pituitary adenoma cell line, AtT20, with an ICso value of 50 nM. Systemic application of the CRF receptor antagonist (0.16mg/kgi.p.) blocked recombinant human interleukin-ll3 (5p.g/kgi.p.) induced fever in rats. The CRF receptor antagonist CP 154,526 (lmg/kgi.p.) also exhibited signs of anxiolytic-like activity in the elevated plus-maze test in rats.